



## (51) International Patent Classification:

A61K 48/00 (2006.01) C12N 5/0789 (2010.01)  
C12N 15/86 (2006.01)

Massachusetts 02210 (US). **PARMAR, Kush M.**; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).

## (21) International Application Number:

PCT/US2022/025081

(74) Agent: **SHORE, David E.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

## (22) International Filing Date:

15 April 2022 (15.04.2022)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/175,249 15 April 2021 (15.04.2021) US

(71) Applicant: **ENSOMA, INC.** [US/US]; 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).

(72) Inventors: **BASHYAM, Ashvin Reddy**; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).  
**ROY, Soumitra**; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston, Massachusetts 02210 (US). **PETERS, Robert Thomas**; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

## (54) Title: ADENOVIRAL GENE THERAPY VECTORS




Fig. 3

(57) Abstract: The present disclosure includes adenoviral vectors characterized by efficient transduction of hematopoietic cells (e.g., one or more particular types of hematopoietic cells), e.g., for in vivo or ex vivo gene therapy. The present disclosure includes, among other things, Ad3, Ad5, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad35, Ad37, and Ad50 vectors and genomes. Ad3, Ad5, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad35, Ad37, and Ad50 vectors and genomes of the present disclosure can include therapeutic payloads.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

**(88) Date of publication of the international search report:**

24 November 2022 (24.11.2022)